HEMAB THERAPEUTICS HOLDINGS
COAGNASDAQTrading Snapshot
- Day Range
- $51.77 – $52.50
- 52-Week Range
- $23.00 – $53.61
- Volume
- $2.45B
- Avg Volume
- $2.12B
- Shares Outstanding
- 46.7M
- Next Earnings
- Oct 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $176M
- Last Q Revenue
- $47M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own COAG
- ✓High-growth profile — revenue up +3.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 40% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About HEMAB THERAPEUTICS HOLDINGS
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60
HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.
Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) Estimate
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.52) by 53.85 percent. This is a 93.8 percent increase over losses of $(12.91) per
Biotech IPO Gains Crush AI Listings With Standout 55% Return
(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders. Learn why COAG stock is a buy.
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026 Preclinical data for sutacimig in Factor VII deficiency (FVIID) demonstrate restoration of thrombin generation under disease-mimicking conditions and support its potential as a pan-hemostatic agent Natural history studies in Glanzmann thrombasthenia (GT) confirm lifelong bleeding burden and critical underutilization of prophylaxis, underscorin
Hemab Therapeutics Presents Clinical, Preclinical Data From Sutacimig In Glanzmann Thrombasthenia And Factor VII Deficiency At International Society On Thrombosis And Haemostasis 2026 Congress
Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today presented clinical